Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Apr 20;11(4):92-94.
doi: 10.1002/cld.710. eCollection 2018 Apr.

The epidemiology of nonalcoholic steatohepatitis

Zobair M Younossi  1   2
Affiliations
Review

The epidemiology of nonalcoholic steatohepatitis

Zobair M Younossi. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of NAFLD in different regions of the world.
Figure 2
Figure 2
A simplified version of the natural history of NAFLD and NASH.
See this image and copyright information in PMC

References

    1. GBD 2015 Obesity Collaborators ; Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med 2017;377:13‐27. - PMC - PubMed
    1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67:328‐357. - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease: meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73‐84. - PubMed
    1. Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, et al. Diagnostic modalities for non‐alcoholic fatty liver disease (NAFLD), non‐alcoholic steatohepatitis (NASH) and associated fibrosis. Hepatology; doi:10.1002/hep.29721. - DOI - PubMed
    1. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander‐Tetri BA, et al. Current and future therapeutic regimens for non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH). Hepatology; doi:10.1002/hep.29724. - DOI - PMC - PubMed